leadf
logo-loader
viewImugene Ltd

Imugene CEO says FDA IND approval for PD1-Vaxx is 'huge news' for the company

Imugene Ltd's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong speaks to Proactive's Andrew Scott after announcing they've received US Food and Drug Administration (FDA) Investigational New Drug (IND) approval to initiate a phase-1 clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx in the USA. The approval allows Imugene to initiate patient recruitment and dosing in its phase-1 clinical study in non-small cell lung cancer (NSCLC) patients.

Quick facts: Imugene Ltd

Price: 0.11 AUD

ASX:IMU
Market: ASX
Market Cap: $521.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Imugene CEO says PD1-Vaxx could be 'paradigm shift' in oncology

Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong speaks to Proactive's Andrew Scott following the news they've dosed the first patient in a Phase I clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx, in Melbourne, Australia. The trial is recruiting patients with non-small...

on 1/12/20

2 min read